Lebecetin, a C-Type Lectin, as Neovascularization Inhibitor
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,191,807 | Lebecetin, a C-Type Lectin, as Neovascularization Inhibitor Sorbonne Université, Centre National de la Recherche Scientifique, Inserm (Institut National de la Santé et de la Recherche Medicale) and Institut Pasteur de Tunis In force · High confidence | Sorbonne Université, Centre National de la Recherche Scientifique, Inserm (Institut National de la Santé et de la Recherche Medicale) and Institut Pasteur de Tunis | In force | High confidence |
1 of 1 record shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.